HOME >> MEDICINE >> NEWS
Gastric bypass patients fare better as surgical programs' experience increases

CHICAGO Risk of serious complications and death following gastric bypass surgery for morbid obesity may be reduced substantially when the surgery is performed at high volume centers and the surgeons have reached the 100 case experience, according to an article in the April issue of Archives of Surgery, one of the JAMA/Archives journals.

The number of surgical procedures for morbid obesity has increased by 644 percent in the last decade, according to background information in the article. Although laparoscopic Roux-en-Y gastric bypass surgery has been the "gold standard" operative procedure for the treatment of intractable morbid obesity for more than 30 years, it remains a technically difficult operation that is performed on a high-risk patient population. "As most bariatric surgeons are well aware, morbidly obese patients do not tolerate complications," the authors write. "Complications, such as leaks [of the staple line], often result in catastrophic outcomes for these patients."

Scott A. Shikora, M.D., of Tufts-New England Medical Center, Boston, and colleagues analyzed the medical records of 750 consecutive morbidly obese patients who underwent laparoscopic Roux-en-Y gastric bypass surgery at Tufts-New England Medical Center from March 1998 to April 2004 to evaluate the role of experience and patient volume in reducing the rate of complications in patients undergoing this type of surgery. Eighty-five percent of the patients were female, with a mean age of 41 years. Their body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) ranged from 32 to 86 (a BMI greater than 29.9 is considered obese) with an average BMI of 47.

The overall complication rate was 15 percent with a death rate of 0.3 percent, according to the authors. But for the first 100 cases, the overall complication rate was 26 percent with a death rate of one percent. This complication rate decreased to approximately 13 percent and wa
'"/>

Contact: Leigh Lucas
617-636-0200
JAMA and Archives Journals
18-Apr-2005


Page: 1 2

Related medicine news :

1. Gastric bug link to irregular heart rhythm
2. Researchers begin randomized double-blind trial of airway bypass treatment for emphysema
3. Experts debate role of stenting, bypass surgery in left main coronary artery disease
4. Jefferson scientists find that plavix appears to be safe during and after heart bypass
5. Jefferson scientists find that drug-eluting stents are disappointing in bypass grafts -- sometimes
6. For super-obese patients, duodenal switch beats gastric bypass
7. New scoring system predicts gastric bypass surgery risk
8. Higher rates of infection may explain why women have higher risk of death after bypass surgery
9. Researchers isolate causes of cognitive loss following coronary artery bypass surgery
10. After gastric bypass surgery, important to check vitamin B1 deficiency
11. Study confirms that stents releasing medication help keep heart bypass vein grafts open

Post Your Comments:
(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... Association (AOA) and the Entertainment Industries Council (EIC) ... TV series American Horror Story on a first-of-its-kind ... the dramatic realities of illegal and unsafe lens ... which has already reached tens-of-thousands, is now releasing ...
(Date:7/24/2014)... -- A new formulation of a powerful narcotic painkiller ... drug has been approved by the U.S. Food and ... Purdue Pharma, the pill is a combination of the ... euphoric effects of oxycodone. The naloxone is only activated ... according to the FDA. While Targiniq has only ...
(Date:7/24/2014)... 17, 2014, Cleveland: Could the body,s own immune system ... associated with conditions like chronic epilepsy, Alzheimer,s dementia and ... study published online by PLOS ONE . , ... known as S100B, which serves as a biomarker for ... brain and spinal column. However, following a brain injury, ...
(Date:7/24/2014)... July 24, 2014 National Analysts Worldwide, ... that it will operate globally under the name, ... a woman-owned Employee Stock Ownership Plan (ESOP) organization led ... McDonald, Ph.D . The firm guides market strategy ... analytics. , Said McDonald, “We wanted our name ...
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & Modifiers ... Poultry, Cattle, Pets, Aquaculture, and Others) - Global Trends ... palatability enhancers & modifiers market with an analysis and ... of types of feed flavors, sweeteners, and text rants. ... spread through 275 pages and in-depth TOC on "Feed ...
Breaking Medicine News(10 mins):Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Immune response may cause harm in brain injuries, disorders 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4
(Date:7/24/2014)...  Blueprint Medicines (Blueprint), a leader in discovering highly ... announced the appointment of Jeffrey Albers as ... Algeta ASA, where he served on the executive management ... Bayer. Mr. Albers succeeds Alexis Borisy , co-founder ... Rock Ventures, who will remain an active member of ...
(Date:7/24/2014)... SAN DIEGO , July 24, 2014 /PRNewswire/ ... the industry leader in bioactive lipid-targeted therapeutics, reported ... trial where ASONEP™ is being investigated as a ... patients that have failed at least one therapy ... and no more than one mTOR inhibitor (e.g., ...
(Date:7/24/2014)... 24, 2014  Market Diagnostics International LLC ("MDxI") ... LabFile , a data resource that sets a ... universe and identifying target In Vitro Diagnostics (IVD) ... that provides IVD manufacturers with accurate and comprehensive ... clear and consistent definitions of laboratory categories and ...
Breaking Medicine Technology:Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2
Cached News: